{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:04:03Z","timestamp":1793127843757,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"French Society of Rheumatology","award":["2\u00e8me Ann\u00e9e 2019"],"award-info":[{"award-number":["2\u00e8me Ann\u00e9e 2019"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>PsA is a chronic inflammatory arthritis with heterogeneous disease manifestations. Data on the prevalence of PsA in adults differ widely depending on the study and the country. This study aimed to estimate the prevalence and incidence of PsA in France, characterize comorbidities associated to PsA and identify prescribed treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This nationwide cohort study involved the administrative healthcare database (Syst\u00e8me National des Donn\u00e9es de Sant\u00e9) of the French health insurance scheme linked to the national hospital discharge database. All adults with PsA registered in the database and identified with a specific International Classification of Diseases, 10th revision code (M07) were included between 1 January 2015 and 31 December 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 63\u2009598 patients were identified as having PsA [55.9\u2009years (s.d. 14.4), 45.6% males]. The prevalence of PsA was estimated at 0.1% and the incidence at 8.4 per 100\u2009000 person-years in the general population. The most common comorbidities were hypertension, diabetes, chronic obstructive pulmonary disease and dyslipidaemia. The prevalence of treatment with conventional synthetic DMARDs (csDMARDs), biological or biosimilar DMARDs (b\/bsDMARDs) and apremilast for PsA was 25.9% (16\u2009453), 30.4% (19\u2009325) and 3.5% (2231), respectively. Overall, 8966 (14.1%) patients were new users of csDMARDs, 8311 (13.1%) were new users of b\/bsDMARDs and 1529 (7.4%) were new users of apremilast. The most common first-line csDMARD was methotrexate (70.9%) and the most frequent first-line b\/bsDMARD was adalimumab (30.8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results lead to a better understanding of PsA. Results were similar to those from other published studies using other data sources, which highlights the reliability of insurance databases for studies.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa448","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T03:19:03Z","timestamp":1593573543000},"page":"1243-1251","source":"Crossref","is-referenced-by-count":50,"title":["Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-1148","authenticated-orcid":false,"given":"Laura","family":"Pina Vegas","sequence":"first","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), EA7379, Paris-Est University, UPEC, Cr\u00e9teil, France"},{"name":"Department of Rheumatology, Mondor Hospital (AP-HP), Paris Est Cr\u00e9teil University, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), EA7379, Paris-Est University, UPEC, Cr\u00e9teil, France"},{"name":"Department of Dermatology, Mondor Hospital (AP-HP), Paris Est Cr\u00e9teil University, Cr\u00e9teil, France"},{"name":"Clinical Investigation Center 1430, INSERM, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Penso","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), EA7379, Paris-Est University, UPEC, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Claudepierre","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), EA7379, Paris-Est University, UPEC, Cr\u00e9teil, France"},{"name":"Department of Rheumatology, Mondor Hospital (AP-HP), Paris Est Cr\u00e9teil University, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"2021030705484168100_keaa448-B1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3899\/jrheum.160180","article-title":"Mapping the effect of psoriatic arthritis using the international classification of functioning, disability and health","volume":"44","author":"Gudu","year":"2017","journal-title":"J Rheumatol"},{"key":"2021030705484168100_keaa448-B2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2021030705484168100_keaa448-B3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis: analysis of SpA prevalence","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2021030705484168100_keaa448-B4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2021030705484168100_keaa448-B5","first-page":"1354","article-title":"Incidence and prevalence of psoriatic arthritis: a systematic review","volume":"35","author":"Alamanos","year":"2008","journal-title":"J Rheumatol"},{"key":"2021030705484168100_keaa448-B6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.rdc.2015.07.008","article-title":"Comorbidities in psoriatic arthritis","volume":"41","author":"Husni","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2021030705484168100_keaa448-B7","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/acr.20627","article-title":"Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis","volume":"63","author":"Husted","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2021030705484168100_keaa448-B8","doi-asserted-by":"crossref","first-page":"e000588","DOI":"10.1136\/rmdopen-2017-000588","article-title":"Real-world burden of comorbidities in US patients with psoriatic arthritis","volume":"3","author":"Shah","year":"2017","journal-title":"RMD Open"},{"key":"2021030705484168100_keaa448-B9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies: cardiovascular morbidity in PsA","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2021030705484168100_keaa448-B10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021030705484168100_keaa448-B11","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.3899\/jrheum.140882","article-title":"Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations","volume":"41","author":"Ogdie","year":"2014","journal-title":"J Rheumatol"},{"key":"2021030705484168100_keaa448-B12","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65(Suppl 4","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2021030705484168100_keaa448-B13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurpub\/ckq108","article-title":"Hospitalization admission rates for low-income subjects with full health insurance coverage in France","volume":"21","author":"Tuppin","year":"2011","journal-title":"Eur J Public Health"},{"key":"2021030705484168100_keaa448-B14","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021030705484168100_keaa448-B15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00038-018-1186-3","article-title":"Identifying diabetes cases in health administrative databases: a validation study based on a large French cohort","volume":"64","author":"Fuentes","year":"2019","journal-title":"Int J Public Health"},{"key":"2021030705484168100_keaa448-B16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ard.2004.029207","article-title":"Prevalence of spondyloarthropathies in France: 2001","volume":"64","author":"Saraux","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2021030705484168100_keaa448-B17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/annrheumdis-2013-204436","article-title":"Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort","volume":"74","author":"Costantino","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021030705484168100_keaa448-B18","article-title":"Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database","volume":"doi:10.1111\/jdv.16566.","author":"Grodner","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021030705484168100_keaa448-B19","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021030705484168100_keaa448-B20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jbspin.2017.11.001","article-title":"Treatment strategies for psoriatic arthritis","volume":"85","author":"Schemoul","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2021030705484168100_keaa448-B21","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/imj.14046","article-title":"Comorbidity in psoriatic arthritis and rheumatoid arthritis","volume":"48","author":"Sinnathurai","year":"2018","journal-title":"Intern Med J"},{"key":"2021030705484168100_keaa448-B22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/acr.23094","article-title":"Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study","volume":"69","author":"Jafri","year":"2017","journal-title":"Arthritis Care Res"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/3\/1243\/36434338\/keaa448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/3\/1243\/36434338\/keaa448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:23:29Z","timestamp":1696317809000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/3\/1243\/5903863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9,10]]},"published-print":{"date-parts":[[2021,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa448","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,9,10]]}}}